Deadly Cough Syrup Sparks Criminal Action in India

Indian authorities have initiated legal proceedings against a pharmaceutical company after a tainted cough syrup was linked to the deaths of 14 children. The syrup contained dangerously high levels of diethylene glycol, leading to accusations of homicide and drug adulteration. This incident raises significant concerns about India's pharmaceutical export quality.

Indian police have taken legal action against Sresan Pharma, following the deaths of 14 children from contaminated cough syrup containing harmful diethylene glycol. Referred to as the 'pharmacy of the world,' India's pharmaceutical industry faces increasing scrutiny over the safety of its exported products.

A specific batch of the cough syrup named 'Coldrif' tested positive for dangerous chemical levels, 46.28% of diethylene glycol, surpassing the permissible level of 0.1%. A doctor who prescribed the medication has been detained by authorities, as reported by the Deputy Chief Minister of Madhya Pradesh.

The manufacturer could face serious legal consequences, including fines and potential life imprisonment. This case highlights significant regulatory challenges within India's pharmaceutical sector, particularly in ensuring the safety of medications offered both domestically and globally.

(With inputs from agencies.)